Mechanistic Insights into Fosfomycin Resistance: Examination of the FosX Class of Fosfomycin Resistance Proteins by Beihoffer, Lauren Ashley
MECHANISTIC INSIGHTS INTO FOSFOMCYCIN RESISTANCE:
EXAMINATION OF THE FOSX CLASS OF FOSFOMYCIN RESISTANCE PROTEINS
By
Lauren Ashley Beihoffer
Thesis
Submitted to the Faculty of the
Graduate School of Vanderbilt University
in partial fulfillment of the requirements
for the degree of
MASTER OF SCIENCE
in
Biochemistry
December, 2005
Nashville, Tennessee
Approved:
Professor Richard N. Armstrong
Professor David E. Ong
ii
To my family for their love, support, and compassion
and
To my husband Jim, who inspires me everyday.
iii
ACKNOWLEDGEMENTS
I would like to acknowledge all those who contributed to this work.  First of all,
this research would not have been possible without the financial support of the National
Institute of Health and the Vanderbilt Center in Molecular Toxicology.  I am also greatly
indebted to my advisor, Professor Richard N. Armstrong, for his great advice and
generous support, and for teaching me what a scientist should be.  I would also like to
thank all of my lab mates, who not only made daily life more fun, but who greatly inspired
me with their advice and suggestions. I am especially grateful for the kind help of Dr.
Kerry Fillgrove, Dr. Rachel Rigsby, Larry Thompson, and Daniel Brown.
Of course, I could not have been successful during my time as a graduate
student without the love and support of my family.  I am forever grateful to my wonderful
husband Jim, to my loving mother who is also my best friend, and to my brother who
taught me to never take a single moment of my life for granted.
iv
TABLE OF CONTENTS
                                                                                                                                    Page
DEDICATION .................................................................................................................. ii
ACKNOWLEDGEMENTS ................................................................................................iii
LIST OF TABLES ........................................................................................................... vi
LIST OF FIGURES .........................................................................................................vii
LIST OF ABBREVIATIONS............................................................................................. ix
Chapter
I.     INTRODUCTION ......................................................................................................1
          Antibiotics ..............................................................................................................1
          Antibiotic resistance ...............................................................................................2
          The antibiotic fosfomycin ........................................................................................5
          Antimicrobial resistance to fosfomycin ....................................................................7
          Fosfomycin resistance proteins ..............................................................................9
          Evolution of a new enzymatic activity.................................................................... 10
          Purpose ............................................................................................................... 17
II.    MATERIALS AND METHODS................................................................................. 18
          Materials .............................................................................................................. 18
          Methods............................................................................................................... 18
               Expression of B. melitensis FosX..................................................................... 18
               Purification of B. melitensis FosX..................................................................... 19
ESI mass spectrometry of Purified Protein ....................................................... 20
               Determination of metal preference by 31P NMR spectroscopy .......................... 20
Estimation of the turnover number by 31P NMR spectroscopy........................... 20
Determination of the minimum inhibitory concentration of fosfomycin ............... 21
Crystallography of B. melitensis FosX.............................................................. 21
Steady state metal binding analysis using fluorescence spectroscopy.............. 22
Transient state metal binding analysis using stopped-flow spectroscopy .......... 22
Mutant generation ........................................................................................... 22
Expression and purification of mutant M. loti FosX protein ............................... 23
Activity analysis for mutant M. loti FosX protein ............................................... 23
III.   PURIFICATION AND PRELIMINARY CHARACTERIZATION OF THE FOSX
       ENCODED IN THE GENOME OF BRUCELLA MELITENSIS .................................. 25
          Results................................................................................................................. 25
               Expression, purification, and ESI-MS of B. melitensis FosX ............................. 25
               Determination of metal preference by 31P NMR spectroscopy .......................... 25
v               Estimation of the turnover number by  31P NMR spectroscopy.......................... 28
               Determination of the minimum inhibitory concentration of fosfomycin ............... 28
               X-ray Crystallography ...................................................................................... 31
          Discussion ........................................................................................................... 32
IV.    INVESTIGATION OF METAL BINDING KINETICS FOR FOSX PROTEINS........... 34
          Results................................................................................................................. 34
               Steady state metal binding analysis ................................................................. 34
               Transient state metal binding analysis ............................................................. 37
          Discussion ........................................................................................................... 46
V.     MUTAGENESIS OF THE CATALYTICALLY TEPID AND PROMISCUOUS FOSX
        FROM MESORHIZOBIUM LOTI............................................................................. 49
          Results................................................................................................................. 49
          Discussion ........................................................................................................... 54
VI.    CONCLUSIONS .................................................................................................... 56
APPENDIX .................................................................................................................... 59
REFERENCES .............................................................................................................. 60
vi
LIST OF TABLES
Table                                                                                                                              Page
1.     Antibiotic Families and Their Mechanisms of Action..................................................2
2.     Timeline of Antibiotic Discovery, Introduction, and Development of Resistance.........3
3.     The Three Classes of Fosfomycin Resistance Proteins: FosA, FosB, FosX ..............8
4.     Members of the VOC Superfamily .......................................................................... 10
5.     Catalytic Activity and MIC Values for FosX Enzymes .............................................. 12
6.     Summary of Results for MIC Experiments .............................................................. 30
7.     Dissociation Binding Constants for Metal Binding to FosX Proteins......................... 36
8.     Observed Off Rate Constants for Metal Binding...................................................... 45
9.     Summary of Metal Binding Dissociation Constants for the FosX Proteins................ 45
10.   Summary of Catalytic Activity for the Different M. loti FosX Mutants........................ 54
vii
LIST OF FIGURES
Figure                                                                                                                            Page
1.     The bacterial targets of the major classes of antibiotics:
        cell wall biosynthesis, protein synthesis, and DNA replication/repair .........................1
2.     Acquisition and mechanisms of bacterial resistance .................................................4
3.     The structure of fosfomycin ......................................................................................5
4.     MurA (UDP-N-acetylglucosamine-3-enolpyruvyltransferase) catalyzes the enol
        ether transferase of PEP to UDP-GlcNAc, the first committed step in cell wall
        biosynthesis .............................................................................................................6
5.     The inactivation of MurA involves the alkylation of a critical cysteine residue.............7
6.      Reactions catalyzed by the three classes of fosfomycin resistance proteins .............9
7.     The M. loti FosX is a promiscuous enzyme............................................................. 11
8.     The threshold model of evolution............................................................................ 13
9.     Overlay of FosA and FosX active sites ................................................................... 14
10.   Structural comparison of FosX and FosA proteins .................................................. 16
11.    Purification of B. melitensis FosX yields pure protein of the correct molecular
         weight ................................................................................................................... 26
12.    Catalytic activity of the B. melitensis FosX in the presence of various divalent
         metal cations......................................................................................................... 27
13.    31P NMR spectrum of a reaction mixture showing approximately 10%
         conversion of substrate into product ...................................................................... 28
14.    Bacterial growth and resistance on LB plates containing fosfomycin ...................... 29
15.    Induction of protein expression does not significantly alter the MIC value for
         B. melitensis FosX ................................................................................................ 30
16.    Cells transformed with the B. melitensis expression vectogr and grown in the
         presence of copper do not have increased MIC values .......................................... 31
17.    Protein crystals of B. melitensis FosX.................................................................... 32
viii
18.    Steady state analysis of metal binding to the FosX proteins: relative change
         in intrinsic protein fluorescence at 335 nm upon metal titration of
         (a) L. monocytogenes FosX, (b, c) B. melitensis FosX,
         (d, e) C. botulinum FosX ....................................................................................... 35
19.    Diagram illustrating the stopped-flow experimental design used to determine
         kon and koff and the apparent equilibrium dissociation constant ............................... 37
20.    Stopped flow analysis of Cu2+ binding to B. melitensis FosX reveals a two step
         process................................................................................................................. 38
21.    Stopped flow analysis of Mn2+ binding to B. melitensis FosX reveals a two step
         process................................................................................................................. 39
22.    Stopped flow analysis of Cu2+ binding to C. botulinum FosX reveals a two step
         process................................................................................................................. 40
23.    Stopped flow analysis of Mn2+ binding to C. botulinum FosX reveals a two step
         process................................................................................................................. 41
24.    Stopped flow analysis of Mn2+ binding to L. monocytogenes FosX reveals a two
         step process ......................................................................................................... 42
25.    Diagram illustrating the stopped-flow experimental design used to observe koff
         directly .................................................................................................................. 43
26.    Stopped-flow data traces observed upon rapid mixing of the enzyme-metal
         complex with EDTA............................................................................................... 44
27.    Sequence alignment of FosA K+ loop with FosX .................................................... 49
28.    Activity of M. loti FosX containing mutations for a K+ binding loop .......................... 51
29.    Activity of M. loti FosX containing the K+ loop mutations and
         E44G/F46Y/M57S mutant background .................................................................. 52
30.    Sequence alignment and computational modeling reveal residues that
         need to be mutated in M. loti FosX to enhance GSH binding.................................. 53
ix
LIST OF ABBREVIATIONS
DNA Deoxyribonucleic acid
MurA                    Uridine-5’-diphospho-N-acetyl-D-glucosamine-3-enolpyruvyltransferase
PEP      Phosphoenolpyruvate
UDP-GlcNAc Uridine-5’-diphospho-N-acetyl-D-glucosamine
GSH Glutathione
GST Glutathione-S-transferase
VOC Vicinol oxygen chelate
LB Luria-Bertani Media
MIC Minimum inhibitory concentration
IPTG Isopropyl-β-D-thiogalactopyranoside
DTT Dithiothreitol
EDTA Ethylenediamine tetraacetic acid
TRIS Tris(hydroxymethyl)aminomethane
HEPES N-(2-hydroxyethyl)piperazine N’-(2-ethanesulfonic acid)
MOPS 3-(N-morpholino)-propanesulfonic acid
DEAE Diethylaminioethyl
TMA Tetramethylammonium
OD600 Optical density at 600 nm
NMR Nuclear magnetic resonance
ESI-MS Electrospray ionization mass spectrometry
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
1CHAPTER I
INTRODUCTION
Antibiotics
Prior to the 1930’s, bacterial infections were the major cause of death in humans
(1). Consequently, the discovery and development of compounds capable of inhibiting
microbial growth was a major milestone in the history of medicine. These compounds,
termed antibiotics, were first introduced into the clinical setting over 60 years ago, and
since that time, have remained the primary treatment for bacterial diseases.
Antibiotics function to kill pathogenic bacteria by selectively targeting processes
necessary for bacterial growth and survival, with the main targets being cell wall
biosynthesis,  protein synthesis, and DNA replication and repair (Figure 1). The major
families of antibiotics that utilize these mechanisms are shown in  Table 1.
Figure 1.  The bacterial targets of the major classes of antibiotics:  cell wall biosynthesis,
protein synthesis, and DNA replication/repair.
Cell Wall Biosynthesis
Protein Synthesis
DNA Replication and Repair
2Table 1.  Antibiotic Families and Their Mechanisms of Action
Major Antibiotic Families Mechanism of Action
Penicillin, cephalosporins, carbapenems,
daptomycin, monobactams, glycopeptides
Inhibition of cell wall synthesis
Tetracyclines, aminoglycosides, oxazolidonones,
streptogramins, ketolides, macrolides, lincosamides
Inhibition of protein synthesis
Fluoroquinolones Inhibition of DNA synthesis
Although antibiotics were initially triumphantly successful in treating diseases once
thought to be incurable—such as tuberculosis and pneumonia—their efficacy has been
compromised by the rapid appearance of antimicrobial resistance.
Antibiotic Resistance
Unfortunately, bacteria are constantly developing strategies by which to combat
the action of antibiotics (2). Antibiotic resistance usually emerges quickly after
introduction of the drug into the clinic and consistently appears as new drugs are
introduced (3) (Table 2).  In fact, drug discovery and development are disproportionate
to the sharp increase in antibiotic resistance seen in the last decade. Consequently, it is
important to understand the mechanisms by which bacteria develop antibiotic resistance
so that new strategies to combat pathogens can be pursued.
3Table 2.  Timeline of Antibiotic Discovery, Introduction, and Development of Resistance
Antibiotic Year Discovered Year Introduced Year Resistance Identified
Penicillin 1929 1940 1943
Streptomycin 1944 1947 1947
Tetracycline 1948 1952 1956
Erythromycin 1952 1955 1956
Vancomycin 1956 1972 1987
Antibiotic resistance is not a novel occurrence, but the problem is expanding at
an alarming rate, being fueled partly by an increase in antimicrobial usage.  Each year,
millions of kilograms of antibiotics are used to treat people as well as animals and
agriculture.  The over-usage and inappropriate usage of antibiotics helps propagate
resistance by killing strains that are susceptible to the drug while selecting for strains
that are resistant, thus giving the resistant bacteria the opportunity to spread and
multiply in the presence of a selective pressure (5). 
There are several ways in which bacteria can become resistant to a particular
antibiotic. Bacteria can acquire antibiotic resistance through mobile genetic elements,
such as plasmids, transposons, or bacteriophages, which carry genes sufficient for
resistance to a particular antibiotic.  Alternatively, step-wise mutations in chromosomal
genes can be used as a method for acquiring drug resistance (Figure 2a).  The
mechanism of resistance typically utilizes one of three strategies: enzymatic alteration or
degradation of the antibiotic, alteration of the drug target,  or alteration of drug uptake or
export from the cell (Figure 2b) (5).
4Figure 2.  Acquisition and mechanisms of bacterial resistance. (a) Bacteria may acquire
resistance to an antibiotic by several different mechanisms: Chromosomal mutation or
obtainment of foreign DNA by transposons, bacteriophages, plasmids, or free DNA. (b)
Strategies utilized by bacteria for resistance to antibiotics: antibiotic degrading enzymes,
antibiotic altering enzymes, and antibiotic efflux pumps.
a.
b.
5The startling effect of antibiotic resistance was made apparent in 1994 when
bacteria isolated from hospital patients were found to be concurrently resistant to all
available antibiotics. This type of multi-drug resistance has become an alarming problem
in pathogens such as Staphylococcus aureus, Streptococcus pneumoniae, and
Salmonella enterica.  Although there are 15 distinct classes of antibiotics, each has been
susceptible to some form of resistance. Even antibiotics that are considered to be the
last line of defense--the fluoroquinolones, vancomycin and carbapenems--have not
escaped resistance by pathogens capable of deadly infection (5).  Further complicating
the issue is the fact that there has been only one new class of antibiotics introduced in
the last 40 years, and the small number of new prospects includes only modified
versions of drugs already in use.  Furthermore, it appears that the resistance problem
will not be entirely solved by the development of new antibiotics, since none so far have
evaded resistance. Antimicrobial resistance has been estimated to cost the United
States up to $24 billion a year, and in 1992 it was ranked the 11th leading cause of death
in the United States (3).
The Antibiotic Fosfomycin
Fosfomycin, (1R, 2S)-epoxypropylphosphonic acid (Figure 3), is an extremely stable
natural product produced by strains of the soil-dwelling bacteria Streptomyces.
Figure 3.  The structure of fosfomycin
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6Fosfomycin was first identified by Merck Research Laboratories in 1969 and was shown
to be a very effective antimicrobial agent, possessing  broad-spectrum antibacterial
activity against both Gram-positive and Gram-negative bacteria. Fosfomycin
demonstrates many pharmacologically desirable properties such as good bioavailability,
low metabolism, and lack of toxicity in humans due to no human target (6).  The
mechanism of action of fosfomycin involves the inactivation of MurA (UDP-N-
acetylglucosamine-3-enolpyruvyltransferase), an enzyme necessary for the first
committed step in cell wall biosynthesis. Specifically, MurA catalyzes the enol ether
transfer of PEP to UDP-GlcNAc (7) (Figure 4).
Figure 4. MurA (UDP-N-acetylglucosamine-3-enolpyruvyltransferase) catalyzes the enol
ether transfer of PEP to UDP-GlcNAc, the first committed step in cell wall biosynthesis.
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7Fosfomycin acts as a substrate analogue of phosphoenolpyruvate and renders the MurA
enzyme inactive through alkylation of an active site cysteine residue (7) (Figure 5).
Figure 5.  The inactivation of MurA involves the alkylation of a critical cysteine residue.
Fosfomycin is currently used to treat lower urinary tract infections and is
classified as a category B drug by the FDA, indicating that it is suitable for use during
pregnancy (8).  In addition, it has been demonstrated that fosfomycin has the potential to
be useful in combinational therapies for treating vancomycin-resistant enterococcal
infections (9) as well as quinolone-resistant strains of E. coli (10), indicating that
fosfomycin is an important and useful antibiotic. Unfortunately, fosfomycin is not exempt
from the mounting resistance problem.
Antimicrobial Resistance to Fosfomycin
Resistance to fosfomycin has developed through three different mechanisms;
alteration of the drug target MurA (11),  alteration of fosfomycin uptake into cells (12,13),
and enzymatic modification and inactivation of the drug by fosfomycin resistance
proteins (14). Enzymes that directly modify and inactivate antibiotics, such as the
fosfomycin resistance proteins, are particularly interesting since they serve as potential
targets for the design of inhibitors.
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8Fosfomycin Resistance Proteins
Plasmid-encoded resistance to the antibiotic fosfomycin was first observed in the
clinic in 1982 after isolation of the transposon Tn2921 from Serratia marcescens (14).
The gene responsible for resistance was later found to encode a 16 kDa glutathione S-
transferase (GST), designated FosA, that inactivates fosfomycin through covalent
attachment of the tri-peptide glutathione (GSH) (15, 16).  This particular GST was not
related to the canonical GST’s, but BLAST searches of  microbial genomes revealed
several genomically encoded proteins possessing high homology to the FosA enzyme.
These enzymes were termed fosfomycin resistance proteins.  The genomically encoded
fosfomycin resistance proteins segregated into three classes based on sequence identity
and type of reaction catalyzed (Figure 6).  They are designated FosA, FosB, and FosX
(Table 3).
Table 3. The Three Classes of Fosfomycin Resistance Proteins: FosA, FosB, and FosX
9Fosfomycin Resistance Proteins
The FosA enzymes are manganese-dependent glutathione S-transferases that
catalyze the nucleophilic addition of the tripeptide GSH to C1 of fosfomycin, opening the
epoxide ring and rendering the drug inactive.  These enzymes show 100-fold activation
in the presence of a monovalent cation such as potassium (18, 19). The FosB enzymes
are magnesium-dependent thiol-transferases that catalyze the addition of L-cysteine to
fosfomycin. The more distantly related FosX proteins are epoxide hydrolases that
catalyze the addition of water to C1 of fosfomycin, giving rise to a diol product (21).  The
FosX enzymes also possess a divalent metal ion requirement.
Figure 6.  Reactions catalyzed by the three classes of fosfomycin resistance proteins.
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Fosfomycin resistance proteins belong to the Vicinal Oxygen Chelate (VOC)
superfamily, which is composed of structurally related metalloenzymes that catalyze
diverse reactions. All members share a paired βαβββ motif, which forms the basic
structural unit of this family.  The superfamily includes enzymes such as glyoxylase I,
extradiol dioxygenase, bleomycin resistance protein, and methylmalonyl-CoA
epimerase, all proposed to have arisen from a common progenitor (17) (Table 4).
Table 4: Members of the VOC Superfamily
Member Reaction Catalyzed
Fosfomycin Resistance
Protein
Nucleophilic opening of
epoxide
Bleomycin Resistance
Protein
None (sequestration)
Extradiol Dioxygenase Oxidative cleavage of C-C
bond
Glyoxalase I Isomerization
           βαβββ motif Methylmalonyl-CoA
Epimerase
Epimerization
Evolution of a New Enzymatic Activity
Kinetic characterization of the FosA encoded by the transposon Tn2921 has
revealed that this highly efficient enzyme not only provides bacteria with robust
resistance to fosfomycin, but has reached kinetic perfection as well, with kcat/Km = (1.4 ±
0.1) x 107.  The FosA enzyme encoded by Pseudomonas aeruginosa has also been well
characterized. Although not as efficient as the TN2921 FosA, this enzyme does show
high catalytic efficiency and provides the native organism with robust resistance to
fosfomycin (20). Much less is known about the more distantly related FosX enzymes,
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however.  Preliminary examination of FosX proteins from a variety of pathogens reveals
a wide range of catalytic activity, with all of the FosX enzymes demonstrating much less
catalytic efficiency than the FosA’s (Table 5) (21).  For example, the FosX enzyme
encoded in the genome of Listeria monocytogenes shows proficient catalytic activity and
nearly all Listeria clinical isolates are inherently resistant to fosfomycin, indicating that
the L. monocytogenes FosX enzyme is functioning as an antibiotic resistance protein in
this organism (22).  Alternatively, the FosX from M. loti, which is not even a human
pathogen, has very poor catalytic activity and there is no evidence of inherent fosfomycin
resistance in this organism.  Additionally, the M. loti enzyme has demonstrated the ability
to catalyze the FosA reaction at very low levels in addition to the FosX reaction for which
it is classified (Figure 7).
Figure 7.  The M. loti FosX is a promiscuous enzyme. 31P NMR shows that it is able to
form both the FosX diol product (16.89 ppm) and the FosA GSH-conjugated product
(18.06 ppm) upon incubation with substrates fosfomycin (11.14 ppm) and GSH.
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This catalytically promiscuous enzyme has low catalytic efficiency for either reaction.
Additionally, the gene encoding the M. loti FosX appears to be in a phosphonate
utilization operon, indicating that it may possess an alternate biological role in the M. loti
organism. It can even be suggested that the M. loti FosX is an intermediate in the
evolution of the fosfomycin resistance proteins. Accordingly, when expressed in E. coli,
the L. monocytogenes FosX enzyme can confer robust resistance to fosfomycin while
the M. loti enzyme cannot confer significant resistance in the biological context of E. coli
(21). These observations (Table 5) suggest that this catalytically poor FosX protein may
possess uncharacterized activity representing its true biological function in the native
organism.
Table 5.  Catalytic Activity and MIC Values for FosX Enzymes
Enzyme kcat/Km (M
-1s-1) Promiscuity
(FosA Activity)
MIC*
(mg/mL Fos.)
TN2921 FosA (1.4 ± 0.1) x 107 No > 25
P. aeruginosa FosA (9.0 ± 1.4) x 105 No > 25
L. monocytogenes FosX (9.0 ± 2.0) x 104 No >25
M. loti FosX (5.0 ± 0.6) x 102 Yes (0.006 s-1) < 0.025
*MIC is the minimum inhibitory concentration of fosfomycin when protein is expressed in
  E. coli.
It is possible that fosfomycin resistance proteins originated from detoxication
enzymes or phosphonate utilization enzymes which underwent mutation to generate
altered catalytic ability for survival in the presence of fosfomycin. It is important to
emphasize the fact that fosfomycin is a natural product produced by soil microbes for
self-defense against other pathogens, meaning that exposure of bacteria to this
compound is not a recent, man-made occurrence. The possibility that the M. loti FosX is
an intermediates in the catalytic alteration of a progenitory enzyme is supported by the
13
observation of catalytic promiscuity and weak catalytic activity of M. loti FosX. This
concept can be rationalized by the threshold model of evolution for generation of a new
enzymatic activity. The evolution of a new enzymatic activity has been suggested to
occur through gene duplication and adaptive evolution events, resulting in enzyme
superfamilies (like the VOC family) that share common mechanistic features but that
catalyze very diverse reactions. Catalytic promiscuity may play a role in this process by
conferring a selective advantage to a duplicated gene. Several enzymes have
demonstrated the ability to catalyze alternative reactions at very low levels, with these
alternative activities being separate and distinct from the native biological reactions
catalyzed by the enzymes. A duplicated gene possessing promiscuous activity at an
appropriate level may offer a selective advantage that would encourage the
development of a novel enzymatic activity.  This hypothesis is presented as a threshold
model for evolution of a new activity (Figure 8) (23).
Evolutionary Starting Points:
1 = Inactive progenitor: many mutations required
2 = Promiscuous progenitor: few mutations required
3 = Promiscuous progenitor: no mutations required
Figure 8  The threshold model of  evolution. (Adapted from O’Brien, P., et al. (1999)
Chemistry & Biology, 6, R91-R105).
1
2
3
Threshold for
selective advantageCatalytic Activity
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Preliminary observations of FosX activity gave rise to site-directed mutagenesis
experiments in order to identify residues critical for proficient catalytic activity as well as
those involved in converting promiscuous FosX activity into the proficient, evolutionarily
advanced FosA activity. Examination of protein crystal structures and initial mutagenesis
experiments have revealed a conserved active site glutamate (the corresponding
residue in FosA is a glycine) that plays a vital role in catalysis, possibly acting as a
general base to facilitate addition of water to fosfomycin (Figure 9).  Mutating this
residue to glycine virtually abolishes the catalytic activity of the enzyme (21).
Figure 9.  Overlay of FosA and FosX active sites. Blue residues indicate FosA residues,
while the multi-colored residues represent the FosX protein. Note that the fosfomycin is
present in the FosA structure only.
In the M. loti FosX, the mutation of E44G was made in addition to two more active site
residues, F46Y and M57S, which amazingly not only abolished FosX activity, but
increased the promiscuous FosA activity of this enzyme 250-fold (Fillgrove, unpublished
15
data).  This triple mutant inspired closer structural examination of FosA and FosX
proteins to reveal residues that are important and distinct for FosA verses FosX activity.
Comparison of crystal structures of FosA and FosX proteins (Figure 10a) reveals
the presence of a potassium-binding loop in FosA that is absent in FosX (Figure 10b)
(21).  Although the role of the potassium-binding loop in catalysis is not completely clear,
the residues comprising the loop are of particular interest for mutagenesis in both the
FosA and FosX proteins.  It is known that potassium provides 100-fold activation for
FosA catalysis, and it is expected that insertion of the loop into FosX through site-
directed mutagenesis will yield similar activation.  Additionally, computational modeling
was used to dock GSH onto the crystal structure of the P. aeruginosa FosA, revealing
residues that may be important for GSH binding in this enzyme.  This information will
also play a role in mutagenesis experiments aimed at transforming M. loti FosX’s
promiscuous activity into a proficient FosA activity.
16
FosA       FosX
a
b
Figure 10.  Structural comparison of FosX and FosA proteins. (a) Ribbon diagrams of
the FosA from Pseudomonas aeruginosa and the FosX from Mesorhizobium loti. (b)
Diagram illustrating the residues forming the K+ binding loop in FosA proteins.
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Purpose
As the antimicrobial resistance problem continues to escalate, there is a critical
need for the development of novel therapies to combat resistant, life-threatening
microbes.  A comprehensive understanding of the molecular basis of resistance will aid
the development of new strategies to treat bacterial infections. Furthermore, enzymes
that directly modify and inactivate antibiotics are particularly interesting since they serve
as potential targets for inhibitors. The goal of this work was to study the enzymology of
the antibiotic-altering FosX protein from the human pathogen Brucella melitensis and
from the soil microbe Mesorhizobium loti in order to gain a better understanding of
genomically-encoded fosfomycin resistance.
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CHAPTER II
MATERIALS AND METHODS
Materials
Escherichia coli BL21(DE3) cells were from Novagen (Madison, WI). Isopropyl-β-
D-thiogalactopyranoside (IPTG) and dithiothreitol (DTT) were from RPI (Mt. Prospects,
IL). Ampicillin, protease inhibitor cocktail, lysozyme, streptomycin sulfate, potassium
phosphate, ethylenediamine tetraacetic acid (EDTA), tris(hydroxymethyl)aminomethane
(TRIS), N-(2-hydroxyethyl)piperazine N’-(2-ethanesulfonic acid) (HEPES), 3-(N-
morpholino)-propanesulfonic acid (MOPS), and glutathione were from Sigma (St. Louis,
MO).  Fosfomycin was from Fluka (Ronkonkoma, NY).  Hydroxylapatite resin and Chelex
100 resin were from BioRad.  DEAE Fast Flow resin was from Amersham Biosciences
(Uppsala, Sweden).  Metals (puratronic grade), as their chloride salts, were from Alfa
Aesar (Ward Hill, MA).  Tetramethylammonium hydroxide (TMAOH) was from Acros.
QuikChange Site-Directed Mutagenesis Kit was from Stratagene (La Jolla, CA) and
Wizard Plus Minipreps DNA Purification System was from Promega (Madison, WI).
Crystallization screens were from Hampton Research and deCODE Genetics.
Methods
Expression of B. melitensis FosX
E. coli BL21(DE3) cells were transformed with a pET-20b expression vector
containing the gene encoding B. melitensis FosX.  Four 2 L cultures were inoculated
with bacteria from starter cultures to reach a starting OD600 = 0.015.  The bacteria were
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grown at 37°C with shaking at 225 rpm until an OD600 = 0.8 was reached.  At this point,
cultures were induced with 600 µM IPTG to stimulate protein expression.  Bacteria
allowed to express protein for four hours.  Cells then harvested by centrifugation and
stored at -80°C.
Purification of B. melitensis FosX
Cell pellets were thawed on ice and resuspended in 75 mL 25mM Tris buffer, pH.
8.2 (buffer A).  To aid cell lysis, 0.1 mg/mL lysozyme was added and cells incubated at
room temperature for 20 minutes with gentle rocking, then incubated on ice for 30
minutes. Protease inhibitor cocktail was added and the cells were lysed by sonication.
Cellular debris was removed by centrifugation (30,000  x g for 25 min).  Nucleic acids
were then precipitated and removed from the cleared lysate by the addition of 700 mg
streptomycin sulfate dissolved in 2 mL H2O, followed by centrifugation (30,000  x g for 25
min.)  Crude lysate was dialyzed against buffer A (all dialysis performed a 4°C and in the
presence of 0.5 mM DTT).  Crude lysate was then passed through a DEAE fast flow
column (2.5 x 13 cm) equilibrated with buffer A.  Column was washed with buffer A and
protein was eluted using a linear NaCl gradient (25-400 mM).  Fractions containing B.
melitensis FosX protein were identified by absorbance at 280 nm and SDS-PAGE
analysis.  Fractions containing the protein were pooled and placed into dialysis against
buffer B (25 mM potassium phosphate, pH 7.5), and then dialyzed against buffer C (25
mM potassium phosphate, pH 6.8).  Protein was then passed through an HA column
(1.5 x 16 cm) equilibrated with buffer C.  Protein was isocratically eluted with buffer C
and the collected protein was dialyzed against the first demetalation buffer, buffer D (20
mM Mops pH 6.8, 100 mM NaCl, 5 mM EDTA, 3 g chelex resin).  Protein was then
dialyzed against the second demetalation buffer, buffer E (25 mM TMA-Hepes pH 7.0,
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10 mM NaCl, 3 g chelex resin) , followed by dialysis in buffer F (25 mM TMA-Hepes, pH
7.5). Protein was concentrated using a nitrogen pressure cell and an Amicon 10K
molecular weight cut-off membrane.  Protein was aliquoted, flash-frozen on dry ice then
immediately stored at  -80°C.
ESI  Mass Spectrometry of Purified Protein
For ESI-MS analysis, 2 pmol/µL protein was prepared in a 1:1 solution of
H2O/ACN with 1% acetic acid.  Sample was then directly injected into a ThermoFinnigan
LCQ ion-trap mass spectrometer (San Jose, CA) in positive-ion mode.
Determination of Metal Preference by 31P NMR Spectroscopy
In a typical reaction, 300nM enzyme was allowed to equilibrate with 100 µM of
metal in 25 mM Hepes, pH 7.5.  Reaction was initiated by the addition of 25 mM
fosfomycin and allowed to proceed for 20 minutes.  Reactions were quenched by the
addition of 50 µL CHCl3 and vigorous vortexing, followed by immediate freezing on dry
ice.  Reactions were thawed and then centrifuged to pellet and remove precipitated
protein. The aqueous layer was demetalated with chelex resin for 3 hours.  Chelex resin
was pelleted and removed and the remaining aqueous layer was used for NMR analysis
after the addition of D2O. Proton-decoupled 
31P spectra of the reactions were collected at
121 MHz, with 31P chemical shifts of 16.9 ppm for diol product and 11.1 ppm for
fosfomycin.
Estimation of the Turnover Number by 31P NMR Spectroscopy
In a typical reaction, 500nM enzyme was allowed to equilibrate with 100 µM
metal  in 25 mM Hepes, pH 7.5.  Reaction was initiated by the addition of 25 mM
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Fosfomycin and allowed to proceed for several minutes.  Reactions were quenched by
the addition of 50 µL CHCl3 and vigorous vortexing, followed by immediate freezing on
dry ice.  Reactions thawed and centrifuged to pellet and remove precipitated protein.
The aqueous layer was demetalated with chelex resin for 3 hours.  Chelex resin was
pelleted and removed and the remaining aqueous layer was used for NMR analysis after
the addition of D2O. Proton-decoupled 
31P spectra of the reactions were collected at 121
MHz. The amount of product formed was then determined from the ratio of peak heights
(for substrate and product) and the amount of substrate used in the reaction, and this
information was used to estimate the turnover for the enzyme.
Determination of the Minimum Inhibitory Concentration of Fosfomycin
E. coli BL21(DE3) cells containing the appropriate expression plasmid were used
to determine the MIC of fosfomycin for various FosX proteins. Cells containing the empty
expression plasmid were used as a control.  Bacteria of OD600 = 0.015 were streaked
onto LB-agar plates containing 100 µg/mL ampicillin,  30 µM glucose-6-phosphate, and
various concentrations of fosfomycin (0-5.0 mg/mL).  Plates were incubated at 37°C for
16 hours and bacterial growth was recorded and photographed.
Crystallography
Protein crystallization screens for B. melitensis FosX protein were performed
using the hanging drop vapor diffusion method using Hampton screens 1 and 2,
Hampton Index screens (Hampton Research), and Wizard screens 1 and 2 (deCODE
Genetics).  Protein concentrations ranged from 8 mg/mL to 16 mg/mL.  Metal (Cu(II) or
Mn (II)) and fosfomycin were used in some screens.
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Steady State Metal Binding Analysis using Fluorescence Spectroscopy
In order to determine the dissociation constant, KD, for metal binding, enzyme
was titrated with increasing amounts of metal in order to observe changes in intrinsic
protein fluorescence.  In a typical experiment, 100 nM enzyme was mixed with
increasing amounts of metal (usual concentration range was from 200 nM to 3.0 µM).
The enzyme-metal complex was excited at 275 nm and fluorescence was observed at
335 nm in a Horiba Fluorolog.  KD was then determined from a plot of relative
fluorescence versus concentration of metal.
Transient State Metal Binding Analysis using Stopped-Flow Spectroscopy
In a typical stopped-flow experiment, 400 nM enzyme was mixed rapidly with
metal (ranging in concentration from 1.2 µM to 180 µM) in an Applied Photophysics
SX17 stopped-flow spectrometer set in fluorescence mode.  The final concentration of
enzyme in the observation cell was 200 nM.  The excitation wavelength was 275 nm and
fluorescence emission was observed above 320 nm.  Data were fit to a double
exponential and kobs values were obtained.  Using the kobs values, on and off rates for
metal binding, as well as apparent dissociation constants for metal binding, were
determined.
Mutant Generation
The QuikChange site-directed mutagenesis kit (Promega) was used in
conjunction with synthetic oligonucleotide primers (Life Technologies) and PCR to
mutate the M. loti FosX expression plasmid.
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Expression and Purification of Mutant M. loti FosX Protein
Mutant protein was expressed the same as for the B. melitensis FosX described
above.  Purification was essentially the same as above but with minor modifications.
Cell pellets were thawed on ice and resuspended in 75 mL 25mM Tris buffer, pH. 7.5
(buffer A). Lysozyme (0.1 mg/mL) was added and cells incubated at room temperature
for 20 minutes with gentle rocking, then incubated on ice for 30 minutes. Protease
inhibitor cocktail was added and the cells were lysed by sonication.  Cellular debris was
removed by centrifugation (30,000  x g for 25 min).  Nucleic acids were then precipitated
and removed from the cleared lysate by the addition of 700 mg streptomycin sulfate
dissolved in 2 mL H2O followed by centrifugation (30,000  x g for 25 min.)  Crude lysate
was dialyzed against buffer A.  Crude lysate was then passed through a DEAE fast flow
column (2.5 x 13 cm) equilibrated with buffer A.  Column was washed with buffer A and
protein eluted using a linear NaCl gradient (25-400 mM).  Fractions containing the
protein were pooled and placed into dialysis against buffer B (25 mM potassium
phosphate, pH 6.9), and then dialyzed against buffer C (25 mM potassium phosphate,
pH 6.8).  Protein was then passed through an HA column (1.5 x 16 cm) equilibrated with
buffer C.  Protein was isocratically eluted with buffer C and dialyzed against the first
demetalation buffer, buffer D (25 mM Hepes pH 7.5, 20 mM NaCl, 500µM EDTA,  3 g
chelex resin), followed by dialysis in buffer E (25 mM TMA-Hepes, pH 7.5).  Protein was
concentrated using a nitrogen pressure cell and an Amicon 10K molecular weight cut-off
membrane.  Protein was aliquoted, flash-frozen on dry ice, and stored at -80°C.
Activity Assays for Mutant Protein
In a typical reaction, 5 µM enzyme was allowed to equilibrate with 100 µM Mn(II)
and 200 mM GSH in 25 mM Hepes, pH 7.5.  The reactions were initiated by the addition
of 25 mM fosfomycin and allowed to proceed for several minutes to an hour.  Reactions
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were quenched by the addition of 50 µL CHCl3 and vigorous vortexing, followed by
immediate freezing on dry ice.  Reactions thawed and centrifuged to pellet precipitated
protein. The aqueous layer was removed and demetalated with chelex resin for 3 hours.
Chelex resin was pelleted and the remaining aqueous layer was used for NMR analysis
after the addition of D2O.
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CHAPTER III
PURIFICATION AND PRELIMINARY CHARACTERIZATION OF THE FOSX
ENCODED IN THE GENOME OF BRUCELLA MELITENSIS
Results
Expression, Purification, and ESI-Mass Spectrometry of B. melitensis FosX
Expression and purification of the B. melitensis FosX protein yielded 15 mg of
pure protein per liter of cell culture (Figure 11a). The calculated molecular weight of the
protein is 16149 Da, which agrees with the molecular weight observed from SDS-PAGE
(protein observed just below the standard marker lysozyme, 20,461 Da, and above
aprotinin, 7,100 Da) and ESI-mass spectrometry (16152 Da) (Figure 11b).
Determination of Metal Preference by 31P NMR Spectroscopy
Activity of the B. melitensis FosX was monitored in the presence of different
divalent metal cations:  Mn2+, Cu2+, Co2+, Mg2+, Zn2+, Ni2+, and Fe2+.  Conversion of
fosfomycin into diol product was observed by 31P NMR (Figure 12).  In the presence of
300 nM enzyme, 25 mM fosfomycin, and 100 µM Cu2+, 42% product conversion was
observed after 20 minutes, the highest conversion observed under these conditions. The
metal preference of the B. melitensis FosX, as judged by percent product conversion
under a standard set of conditions, was Cu2+ > Mn2+ > Co2+ > Ni2+ > Zn2+ > Mg2+ ≈ Fe2+.
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     a
     b
Figure 11. Purification of B. melitensis FosX yields pure protein of the correct molecular
weight.  (a) SDS-PAGE of fractions collected from the HA purification column (b) ESI-MS
of purified B. melitensis FosX protein.
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Figure 12. Catalytic activity of the B. melitensis FosX in the presence of various divalent
metal cations: (a) no metal, (b) Cu2+, (c) Mn2+, (d) Co2+, (e) Ni2+,  (f) Zn2+, (g) Mg2+, (h)
Fe2+
O
P CH3
O
OH
-O
O
P CH3
O
OH
-O
P CH3
O
OH
-O
HO OH
28
Estimation of the Turnover Number by 31P NMR Spectroscopy
The turnover number for the B. melitensis FosX was estimated by looking at the
31P NMR spectra of reaction mixtures that yielded 10-15% product conversion (Figure
13).  Using the peak heights and amount of product formed, the kcat (in the presence of
Cu2+) was estimated to be 36 s-1.
Figure 13. 31P NMR spectrum of a reaction mixture showing approximately 10%
conversion of substrate into product.
Determination of the Minimum Inhibitory Concentration (MIC) of Fosfomycin
The expression plasmids encoding the FosX enzymes from L. monocytogenes,
B. melitensis, C. botulinum, and M. loti were transformed into E. coli cells and grown on
LB-agarose plates containing varying amounts of fosfomycin (0.0 mg/mL to 5.0 mg/mL).
The minimum amount of fosfomycin at which inhibition of bacterial growth was observed
by visual inspection was recorded as the MIC value for the enzyme, where a higher MIC
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value indicates greater resistance.  P. aeruginosa FosA and the empty expression vector
were used as controls.
       0 mg/mL Fosfomycin          0.025 mg/mL Fosfomycin
       0.1 mg/mL Fosfomycin   5 mg/mL Fosfomycin
Figure 14.  Bacterial growth and resistance on LB plates containing fosfomycin. BL21 E.
coli cells were transformed with expression plasmids containing the FosX genes.  Each
plate was divided into six sections of bacterial growth (clockwise from top): 1= empty
expression vector, 2 = B. melitensis FosX, 3 = L. monocytogenes FosX, 4 = M. loti FosX,
5 = C. botulinum FosX, and 6 = PA1129 FosA.
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The only bacterial growth observed above 0.025 mg/mL fosfomycin was from cells
transformed with L. monocytogenes FosX and P. aeruginosa FosA (PA1129). The
results are summarized in Table 6.
Table 6.  Summary of Results for MIC Experiments
Expression Plasmid MIC
Empty vector < 0.025 mg/mL
L. monocytogenes FosX 5 mg/mL
B. melitensis FosX           < 0.025 mg/mL
M. loti FosX           < 0.025 mg/mL
C. botulinum FosX           < 0.025 mg/mL
PA1129 FosA 5 mg/mL
To insure that the B. melitensis FosX was being expressed in the MIC assays, the B.
melitensis FosX plasmid was transformed in Tuner (DE3) E. coli cells so that expression
could be tightly regulated.  Cultures were induced with 25 µM IPTG for one hour prior to
being streaked on the fosfomycin-containing plates.  There was a slight increase in
growth observed, raising the MIC value of B. melitensis FosX to 0.025 mg/mL (Figure
15).  In terms of resistance, however, this increase was insignificant.
       0 mg/mL             0.025 mg/mL          0.1 mg/mL
Figure 15. Induction of protein expression does not significantly alter the MIC value for
B. melitensis FosX.  Tuner cells containing either B. melitensis FosX expression vector
or the empty vector were induced with IPTG to induce protein expression, and then
plated on fosfomycin-containing plates.
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Since it was known from previous experiments that the B. melitensis FosX shows
preference for Cu2+ instead of Mn2+, E. coli cells transformed with the B. melitensis FosX
expression vector were cultured in media containing 200 µM CuCl2 prior to being plated
on agarose plates containing varying amounts of fosfomycin.  The MIC value did not
change in this experiment (Figure 16).
.025
  0.0 mg/mL            0.025 mg/mL
Figure 16.  Cells transformed with the B. melitensis FosX expression vector and grown
in the presence of copper do not have increased MIC values. The left sides of the plates
contain cells grown without the addition of copper, and the right sides of the plates
contain cells grown with the addition of exogenous copper.
X-ray Crystallography
Although initial attempts to crystallize the B. melitensis FosX protein in the
presence of copper were successful (Figure 17), preliminary screening revealed that the
X-ray diffraction pattern was only to about 3 or 4 Å resolution and displayed diffuse
scattering patterns.  Attempts to optimize crystallization conditions did not improve the
quality or resolution of the X-ray diffraction data.
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Figure 17.  Protein crystals of B. melitensis FosX
Discussion
After the initial discovery of enzyme-mediated inactivation of fosfomycin by
fosfomycin resistance proteins, homologues of genomically encoded FosA proteins were
found in a variety of bacteria.  These homologues were later divided into classes
designated FosA, FosB and FosX.  Investigation of FosA protein activity revealed that
these proteins were GSH transferases and all shared a Mn2+ dependency and were
activated by the presence of K+.  Likewise, the FosB enzymes were also thiol-
transferases, but utilized L-cysteine as a co-substrate instead of GSH.  All members of
the FosB class shared a dependency on Mg2+.  The more distantly related FosX
proteins, however, were unique in that no thiol was involved in the reaction mechanism
and instead, these enzymes were found to be expoxide hydrolases.  Initial examination
revealed that the members of FosX required Mn2+ for activity.  Therefore, it was very
surprisisng that the B. melitensis FosX was observed to prefer Cu2+ instead of Mn2+.
This unique metal preference was also observed for the C. botulinum FosX.  Even more
intriguing was the observation that these two enzymes with a different metal preference
could proficiently catalyze the hydrolysis of fosfomycin in vitro, but could not confer
resistance to fosfomycin in the biological context of E. coli.  The turnover number of B.
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melitensis FosX was estimated to be 36 s-1, which is identical to the turnover number of
the L. monocytogenes FosX—the FosX that confers robust resistance when expressed
in E. coli and in the native organism as well.  It appeared that this discrepancy of
catalytic ability of the B. melitensis FosX might be explained by the different metal
preference of this enzyme. To determine if this was the case, a more detailed analysis of
metal binding was carried out and discussed in the following chapter.
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CHAPTER IV
INVESTIGATION OF METAL BINDING KINETICS FOR THE FOSX PROTEINS
Results
Steady State Metal Binding Analysis
In order to determine equilibrium dissociation constants for metal binding to FosX
proteins, the intrinsic protein fluorescence was exploited. Upon titration of 100 µM FosX
protein with metal, changes in fluorescence were observed and plotted as a function of
metal concentration.  The data were fit with the bound verses total equation, which takes
into the account that binding is tight, and hence KD is small.  This equation takes into
consideration that most of the protein is in the protein-metal complex since the
concentration of protein is approximately equal to KD:
Y=  -(-1(Kd + X + Cap) + √((Kd + X + Cap)
2 – (4 X Cap))     (equation 1)
               2
where Cap = [Etotal] • [M
2+
total].  Plots of the experimental data are shown below (Figure
18).
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        a
b         c
d          e
Figure 18. Steady state analysis of metal binding to the FosX proteins: relative change
in intrinsic protein fluorescence at 335 nm upon metal titration of  (a) L. monocytogenes
FosX, (b, c) B. melitensis FosX, (d, e) C. botulinum FosX.
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From the steady state data, it was evident that the B. melitensis FosX and C. botulinum
FosX, the proteins suspected to utilize Cu2+ for activity, demonstrate tighter binding of
Cu2+ than of Mn2+.  In fact, binding of Cu2+ to these enzymes appeared to be tighter than
that of Mn2+ binding to the L. monocytogenes FosX (Table 7).
Table 7.  Equilibrium Dissociation Constants for Metal Binding to FosX Proteins.
FosX Enzyme Metal KD (nM)
L. monocytogenes Mn2+ 789 ± 222
B. melitensis Cu2+ 214 ± 20
B. melitensis Mn2+ 3184 ± 925
C. botulinum Cu2+ 166 ± 39
C.botulinum Mn2+ 444 ± 137
Transient state metal binding analysis
In order to study metal binding in more detail, stopped-flow spectroscopy was
used to make transient state kinetic measurements. These experiments utilized rapid
mixing of 200 nM enzyme and varying concentrations of metal (1.2 µM to 180 µM) so
that changes in intrinsic protein fluorescence could be measured on a millisecond time
scale.  Using this experimental design, on and off rate constants for metal binding were
determined, allowing for the calculation of an apparent equilibrium dissociation constant
(Figure 19). Plotting the observed rate constant as a function of metal concentration
yields a linear relationship where the slope equals kon and the y-intercept equals koff.
Unfortunately, extrapolation of the data was sometimes too close to zero to obtain an
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E + M2+               E•M2+
kon
koff
accurate off rate constant of binding.  In addition, the Prizm software used to analyze the
data did not always result in a good fit of the data.
 kobs = koff + kon [M
2+]
Figure 19. Diagram showing a typical change in fluorescence and illustrating the
stopped-flow experimental design used to determine kon and koff and the apparent
equilibrium dissociation constant.
When the B. melitensis FosX protein was rapidly mixed with Cu2+ in the stopped-
flow, the observed change in intrinsic protein fluorescence was fit to a double
exponential, yielding two distinct observed rate constants.  This implies that metal
binding is a two step process. From the rate 1 data, it was observed that the on rate
constant for metal binding was very fast, and the off rate constant relatively slow, giving
an apparent dissociation constant in the low nanamolar range, thus indicating tight
binding (Figure 20).  Analysis of rate 2 data  was more difficult (Figure 20).  Data were fit
  KD (app) = koff/kon
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to a hyperbola in this case, however it was unclear what information this reveals about
metal binding except for the fact that it is a two step process.
Figure 20.  Stopped flow analysis of Cu2+ binding to B. melitensis FosX reveals a two
step process.  The top plot is of the rate 1 data and the bottom plot is for rate 2 data.
Brucella melitensis FosX
and Cu2+ Binding (rate 2 data)
0 5 10 15 20
0
1
2
3
4
5
     KOFF
     KON
     KD
Std. Error
     KOFF
     KON
     KD
95% Confidence Intervals
     KOFF
     KON
     KD
Goodness of Fit
     Degrees of Freedom
     R squared
-0.3173
7.817
9.362
0.2903
1.552
5.219
-1.567 to 0.9320
1.139 to 14.50
-13.10 to 31.82
2
0.9931
[Cu2+] (µM)
Brucella melitensis FosX
and Cu2+ Binding
0 5 10 15 20
0
10
20
30
40      Slope
     Y-intercept
     X-intercept
     1/slope
95% Confidence Intervals
     Slope
     Y-intercept when X=0.0
     X-intercept when Y=0.0
Goodness of Fit
     r squared
2.089 ± 0.1523
0.2563 ± 1.092
-0.1227
0.4788
1.666 to 2.511
-2.775 to 3.287
-1.857 to 1.174
0.9792
[Cu2+] (µM)
39
Binding of Mn2+ to B. melitensis FosX revealed a much slower on rate constant with
approximately the same off rate constant, yielding an apparent dissociation constant this
time in the low micromolar range.  As with Cu2+ binding, this experiment revealed a two
step process for metal binding (Figure 21).
Figure 21. Stopped flow analysis of Mn2+ binding to B. melitensis FosX reveals a two
step process.
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As with the B. melitensis FosX, analysis of C. botulinum FosX and Cu2+ binding revealed
a fast on rate constant of binding.  The linear regression, however, did not allow for
determination of the off rate constant in this case, since the off rate constant is probably
in actuality very close to zero.  In this case, the off rate constant was determined by an
alternative method, which will be described later in this chapter.  As with previous
stopped-flow experiments, a two step process for metal binding was observed (Figure
22).
Figure 22. Stopped flow analysis of Cu2+ binding to C. botulinum FosX reveals a two
step process.
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C. botulinum FosX binding to Mn2+ demonstrated a much slower on rate constant, which
was to be expected since it was believed that this enzyme prefers Cu2+.
Figure 23. Stopped flow analysis of Mn2+ binding to C. botulinum FosX reveals a two
step process.
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Analysis of L. monocytogenes binding to Mn2+ revealed a two step binding process as
well, with a relatively slow off-rate constant, giving an apparent dissociation constant in
the nanamolar range.
Figure 24. Stopped flow analysis of Mn2+ binding to L. monocytogenes FosX reveals a
two step process.
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Although the stopped-flow data supplied us with much information, in most cases, the off
rate constant for metal binding was unreliable since the y-intercept of the linear
regression was too close to zero.  To observe off rate constants directly so that a more
accurate dissociation constant could be determined, the experiment illustrated in Figure
25 was used.
Figure 25.  Diagram illustrating the stopped-flow experimental design used to observe
koff directly.
This experiment utilized and excess of EDTA (25 mM) to trap the metal so that off rate
constants could be directly observed using stopped-flow instrumentation (Figure 26).
From the data, it was evident that the off rate for Mn2+ from L. monocytogenes FosX is
extremely slow, as would be anticipated for an enzyme that binds a metal so tightly.  The
B. melitensis FosX and C. botulinum FosX have relatively slow off rates for Cu2+ binding,
while the off rate for Mn2+ binding to C. botulinum is relatively fast (Table 8).
E  +  M2+E M2+
Trap with EDTA
EDTA M2+
koff
kon
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      a b
      c d
Figure 26.  Stopped-flow data traces observed upon rapid mixing of the enzyme-metal
complex with EDTA  (a) Cu2+ and B. melitensis FosX  (b) Mn2+ and L. monocytogenes
FosX  (c) Cu2+ and C. botulinum FosX (d) Mn2+ and C. botulinum FosX.
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Table 8. Observed Off Rate Constants for Metal Binding
FosX Enzyme Metal Observed koff (s
-1)
L. monocytogenes Mn2+ 0.00168 ± 0.00007
B. melitensis Cu2+ 0.372 ± 0.001
B. melitensis Mn2+ n.d.
C. botulinum Cu2+ 0.233 ± 0.002
C.botulinum Mn2+ 1.80 ± 0.14
 
                   n.d. = not determined
Overall, the steady state metal binding data agrees well with the data from the transient
state experiements.  From the data, it is apparent that the B. melitensis and C. botulinum
FosX proteins demonstrate a preference for Cu2+ due to their low dissociation constants
and reasonably slow off rates of Cu2+ binding, in addition to displaying higher catalytic
activity in the presence of Cu2+. (Table 8).  Therefore, it would be reasonable to expect
that Cu is indeed the metal utilized by these enzymes in their native organisms.
Table 9. Summary of Metal Binding Dissociation Constants for the FosX Proteins
FosX Enzyme Metal KD (steady-
state) (nM)
KD
(presteady-
state) (nM)
Observed koff
(s-1)
KD  (from
observed
koff) (nM)
L. monocytogenes Mn2+ 789 ± 222 445.0 ± 0.41 0.00168 ±
0.00007
4.0 ± 0.04
B. melitensis Cu2+ 214 ± 20.4 122 ± 4.3 0.372 ± 0.001 178 ± 2.7
B. melitensis Mn2+ 3184 ± 925 3056.9 ± 0.63 n.d. n.d.
C. botulinum Cu2+ 166 ± 39.1 n.d. 0.233 ± 0.002 39.5 ± 0.01
C.botulinum Mn2+ 444 ± 137 15607 ± 0.4 1.8 ± 0.1 36137 ± 0.3
n.d. = not determined
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Discussion
The data from the steady state and transient state binding studies agree well with
the metal preferences first observed by 31P NMR for the FosX enzymes; unlike the Mn2+-
dependent M. loti and L. monocytogenes FosX enzymes, the FosX enzymes encoded by
B. melitensis and C. botulinum demonstrate a preference for Cu2+ as their divalent metal
cation.  This is supported by their low equilibrium dissociation constants and slow off
rates of Cu binding as compared to Mn.  Although the transient state kinetic data
revealed that metal binding is a two step process, the  inability of the software to
completely distinguish the second observed rate constant from the first observed rate
constant led to inconsistent rate 2 data.  Therefore, fitting rate 2 data was difficult and
was unable to reveal the nature of the second step of the metal binding process.  Since
these proteins exist as dimers, however, one might speculate that a two step process is
observed due to cooperativity of metal binding.  However, in the case of cooperativity,
the rate 2 data would be expected to yield a linear relationship, not a hyperbolic one as
seen in the data above.  Although not yet conclusive, it appears that the second step we
are observing is not due to cooperativity but to some other conformational change of the
enzyme-metal complex.
In addition, the data support metal preference as the explanation for the variable
biological activity observed in E. coli.  Research has suggested that bacteria maintain
levels of Cu and Mn in the range of 10 to 100 µM.  However, the theory of a “free” metal
pool in the case of Cu is beginning to seem impractical. Cu is one of the more toxic
metals that a cell requires.  The intracellular concentration must be controlled in order to
prevent damage caused by this toxic, redox-active metal. Consequently, free forms of
Cu are proposed to be too low in a cell to allow an apoprotein to obtain Cu.  So how
does an apoprotein obtain the necessary Cu cofactor? The answer lies in a system of
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enzymes whose job is to control the amount and location of Cu within a cell.  Intracellular
metal trafficking systems are composed of copper transport ATPases and metal
chaperones which are in charge of  regulating, sequestering, and allocating Cu to the
appropriate metalloenzymes (24).  One of the best studied bacterial copper transport
systems is the Enterococcus hirae system, which utilizes three proteins:  the ATPase
proteins CopA and CopB, and the copper chaperone CopZ (25).
Copper chaperones are small cytoplasmic proteins that are responsible for
delivering Cu to Cu-dependent enzymes so that the free pool of available metal can be
kept low in the cell.  Interestingly, BLAST searches revealed a CopZ homolog in Brucella
melitensis that is not present in E. coli.  Further investigation revealed that since E. coli
does not encode a true, stand-alone copper chaperone, it actually may generate a
copper chaperone by proteolytic cleavage of its Cu-ATPase (26).  Whatever the case, it
is clear that there is large diversity when it comes to bacterial organization of the genes
encoding the copper trafficking system, i.e. Cu-ATPase proteins and copper
chaperones, giving rise to diversity in copper trafficking.  If this is indeed the case, it may
help explain why a Cu-dependent enzyme from B. melitensis may be unable to acquire
the metal cofactor it needs in the biological setting of E. coli.
Taking this into consideration, it is apparent that metal preference of FosX
proteins may play a role in the unexpected observations of the MIC assays.  The Cu-
dependent, catalytically proficient FosX enzymes from B. melitensis and C. botulinum
may be unable to provide resistance in E. coli due to the unavailability of the necessary
metal cofactor, not because they are inefficient at hydrolyzing fosfomycin in a biological
setting.  Although these enzymes can utilize Mn2+ in vitro, and there is likely to be a
“free” pool of Mn in E. coli, the KD values for Mn
2+ binding to these proteins are most
likely too high to allow for efficient acquisition of metal in E. coli, thus explaining the
discrepancy observed between in vitro and in vivo catalytic ability.
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Although true MIC values cannot be obtained using the MIC assays described in
this work, it is reasonable to expect that the B. melitensis FosX is quite capable of
providing the B. melitensis organism with resistance to fosfomycin, especially
considering that this enzyme’s in vitro activity is virtually the same as the in vitro activity
of the biologically active L. monocytogenes FosX.  Likewise, it is also reasonable that
the C. botulinum FosX should provide some resistance to the botulinum organism even
though it displays weaker catalytic activity in vitro.  Although an attempt was made to
supplement copper to growing E. coli cells in the MIC assays, it is not surprising that the
copper transport and trafficking system in E. coli did not allow accumulation of this toxic
metal to a concentration that would be adequate for metal acquisition by an apoprotein.
To resolve this discrepancy, MIC assays would need to be performed in the native
organism, which in the case of these two extremely pathogenic organisms, remains
impossible in our current environment.
49
CHAPTER V
MUTAGENESIS OF THE CATALYTICALLY TEPID AND PROMISCUOUS FOSX FROM
MESORHIZOBIUM LOTI
Results
Creation of a K+ Binding Loop in M. loti FosX
In an attempt to enhance the promiscuous and catalytically poor FosA activity of
the M. loti FosX, residues capable of forming a K+ binding loop were inserted by
mutation of existing residues.  It is proposed that the ability to bind K+ is important for
FosA catalytic activity, and would therefore enhance the poor FosX activity of this
enzyme and perhaps even its promiscuous FosA activity as well.
The residues comprising the K+ binding loop in FosA were elucidated by
structural observation and sequence alignments.  The residues comprising the loop in P.
aeruginosa FosA are underlined below (Figure 27).
P. aeruginosa FosA 87REWKQNR---SEGDSFYFL102
Tn2921 FosA     TIWKQNK---SEGASFYFL
M. loti FosX 92DMRPPRPRVEGEGRSIYFY110
L. monocytogenes FosX     EMKPERPRVQGEGRSIYFY
Figure 27. Sequence Alignment of FosA K+ Loop with FosX.  The underlined residues
represent those involved in interaction with K+.
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This sequence alignment revealed that the corresponding residues in FosX contained an
insertion of three residues and the region was overall dissimilar to FosA.  In order to
create a functional  K+ binding loop analogous to the loop in FosA, the following
mutations were made in the M. loti FosX DNA using the QuikChange method of site-
directed mutagensis: ΔR99/ΔV100/ΔE101/P96Q/R97N/P98R/G102S. The same set of
mutations were made in the E44G/F46Y/M57S mutant (active site mutations which yield
a 250-fold enhancement of FosA activity) background as well.  When the activity of
these mutants was evaluated, no enhancement of FosX or FosA activity was observed
in the presence of K+.  In fact, overall catalytic activity was actually decreased (Figures
28 and 29).
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   a        b  c       d           e
        f             g
Figure 28.  Activity of M. loti FosX containing mutations for a K+ binding loop.
Fosfomycin is seen at 11.1 ppm, diol product is at 16.9 ppm and the FosA GSH-
conjugated product is seen at 18.1 ppm. (a) 31P NMR spectrum of TMA-Fosfomycin,
notice that TMA-fosfomycin contains a small amount of diol contaminat at 16.9 ppm
which was subtracted from the other spectra in turnover calculations, (b) WT M. loti (c)
WT M. loti plus K+ (d) K+ loop mutant, no K+ present, (e) K+ loop mutant, plus K+ (f) K+
loop mutant in presence of GSH, no K+ present,(g) K+ loop mutant in presence of GSH,
plus K+
52
                  a    b
Figure 29.  Activity of M. loti FosX containing the K+ loop mutations and
E44G/F46Y/M57S mutant background (a) without presence of K+ (b) in presence of K+.
As noted in Figure 28, the TMA-fosfomycin contains diol contaminant at 16.9 ppm.
A second attempt was made to create a functional K+ binding loop in M. loti
FosX.  In addition to the mutations created previously, the following mutations were
made as well: R94W/P95K/R105D. These mutants were made in the E44G/F46Y/M57S,
ΔR100/ΔV101/ΔE102/P97Q/R98N/P99R/G103S background.  Unfortunately, this mutant
did not demonstrate enhancement of activity in the presence of K+ (Table 10).
In an alternative approach for enhancement of FosA activity, the M. loti FosX was
mutated in an attempt to create a more favorable GSH binding site, which would
consequently enhance the promiscuous FosA activity of this enzyme.  This seemed to
be the necessary next step since the E44G/F46Y/M57S mutant displayed a 250-fold
increase in FosA activity but only at very high concentrations of GSH.  By comparison of
sequence alignments and computational work previously done with P. aeruginosa FosA
(Figure 31), the following mutations were made:  P95K/P98R in the E44G/F46Y/M57S
mutant background.
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a.
   b.
Figure 30.  Sequence alignment and computational modeling reveal residues that need
to be mutated in M. loti FosX to enhance GSH binding. (a) Sequence alignment of FosA
and FosX around the proposed GSH binding site.  (b)  Computational docking of GSH
onto FosA reveals residues proposed to interact with GSH.  The two residues circled in
red correspond to residues that were mutated into M. loti FosX to enhance GSH binding.
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Unfortunately, the attempt to enhance GSH binding in M. loti FosX did not result in
increased FosA activity of this enzyme.  All of the mutagenesis data described above is
summarized in Table 10.
Table 10. Summary of Catalytic Activity for the Different M. loti FosX Mutants
Mutation kcat(FosX)
(s-1)
kcat(FosA)
(s-1)
WT* 0.15 0.06
E44G/F46Y/M57S* n.a. 1.5
K+ Loop (WT background)** 0.002 0.001
K+ Loop/E44G/F46Y/M57S n.a. 0.3
Additional K+ Loop
Mutations/E44G/F46Y/M57S***
n.a. 0.15
P95K/P98R in E44G/F46Y/M57S n.a. 0.06
n.a. = no activity detected
*Kerry Fillgrove, unpublished results
**ΔR99/ΔV100/ΔE101/P96Q/R97N/P98R/G102S
***ΔR99/ΔV100/ΔE101/P96Q/R97N/P98R/G102S plus R94W/P95K/R105D
Discussion
Previous mutagenesis experiments involving the M. loti FosX were successful in
enhancing the weak, promiscuous GST activity of this enzyme (Fillgrove, unpublished
data).  The E44G/F46Y/M57S active site mutations virtually abolished the enzyme’s
FosX activity and increased its promiscuous FosA activity 250-fold.  It was hoped that
further mutagenesis of this interesting enzyme would transform this weak, promiscuous
FosX protein into a  proficient GST, thus revealing the residues that are important and
distinct for FosA activity verses FosX activity and illuminating the role of evolution in the
development of these proteins.
  Mutagenesis of M. loti FosX in this work was intended to elucidate residues that
are important for FosA activity in distinction to FosX activity.  Although creation of a
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functional K+ binding loop and enhancement of GSH binding in M. loti FosX were not
successful, these experiments revealed that there may be other structural components
necessary for binding and utilizing K+ and GSH effectively. A similar idea was also
proposed in studying the FosA encoded by the transpososn Tn2921.  Crystallization of
the completely apo FosA enzyme revealed a highly flexible K+ loop region in the
absence of bound K+, while the active site and Mn2+ binding site did not seem to be
disordered or perturbed.  Perhaps even more intriguing was that NH4
+, which is known to
activate the enzyme, was present in the buffer but was unable to occupy the K+ loop
region.  This raises questions to whether substrate or Mn2+ binding must occur first in
order to structurally orient the K+ binding region to form a functional K+ loop.  This
certainly may explain why simple insertion of K+ binding residues into FosX may not be
sufficient to form a functional binding loop (27).
Alternatively, the P95K/P98R mutations may have been unsuccessful due to the
requirement of a structured K+ binding loop for orienting the GSH binding site.  The
sequence of FosA reveals that the residues comprising the K+ binding loop are adjacent
to those comprisisng the GSH binding resides.  It is probable that without a structured K+
loop, the GSH binding site may not be oriented for effective GSH binding.
 In order to transform the weak, promiscuous FosA activity of the  M. loti FosX
into a proficient GST activity, it appears that a more global approach should be taken in
terms of mutating the active site or GSH binding site to mimic those of the FosA
proteins.
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CHAPTER VI
CONCLUSIONS
The FosX metalloprotein from Brucella melitensis has been  characterized and
shown to be an effective fosfomycin-hydrolysing enzyme, but it is still unclear how
effective this protein is in providing resistance in vivo.  From the  MIC assays performed
in E. coli, the B. melitensis FosX appears to provide no resistance to fosfomycin at all.
This observation was peculiar since in vitro, this enzyme was as proficient as the L.
monocytogenes FosX, which does provide robust resistance to fosfomycin.  It is now
apparent that the origin of this discrepancy between in vitro and in vivo activity seems to
lie in the different metal preferences of the FosX proteins.
The metal binding properties of the B. melitensis and C. botulinum FosX proteins
are particularly intriguing and have suggested that our model organism, E. coli, may not
provide a mimetic intracellular environment in terms of metal availability. Metal binding
kinetics have demonstrated that the B. melitensis and C. botulinum enzymes bind Cu2+
more tightly than Mn2+.  Additionally, these enzymes demonstrate better catalytic activity
in the presence of Cu2+ rather than any other biologically relevant, divalent metal cation.
The reason for this difference in metal preference is not understood at the present time.
The metal binding characteristics, however, do help us to understand why our model
organism E. coli may not be a the best model to use since E. coli seems to possess a
different Cu trafficking system.  Unfortunately, the B. melitensis organism is categorized
as a possible agent of biological warfare, making it impossible for us to work with this
organism in our current environment.  Therefore, we are unable to determine an
appropriate MIC for this enzyme and are unsure of it’s biological potential.  It seems
rational to expect, however, that the B. melitensis FosX is capable of providing the B.
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melitensis organism with robust resistance to fosfomycin, just as the L. monocytogenes
FosX of similar in vitro activity provides L. monocytogenes  with robust
resistance—resistance that is even observable in the clinic.
The diversity of fosfomycin resistance is evidenced within members of the FosX
class.  At first glance, the FosX present in the genome of the soil-dwelling, nitrogen fixing
microbe Mesorhizobium loti appeared to be a catalytically poor enzyme in comparison to
other FosX members.  However, deeper investigation of this enzyme revealed that its
existence may be intended for something other than actual fosfomycin resistance.  For
example, this microbe in not a human pathogen, but it is soil dwelling and therefore
would have had the potential to be exposed to the microbes that synthesize and secrete
fosfomycin.  However, examination of the M. loti genome reveals that the gene encoding
FosX resides in what appears to be an uncharacterized phosphonate utilization operon.
Interestingly, the M. loti FosX is such a catalytically poor enzyme that it is extremely
inefficient at catalyzing the hydrolysis of fosfomycin in vitro and provides absolutely no
resistance to fosfomycin in MIC assays, suggesting it may utilize an alternative
phosphonate compound as substrate.  Even more striking is the fact that this protein is
catalytically promiscuous, being able to catalyze the FosA reaction at very low levels.
Due to its weak catalytic activity and its ability to catalyze an alternate reaction at low
levels, the M. loti FosX may represent an intermediate in the evolution of fosfomycin
resistance proteins; therefore, the M. loti FosX became a tool by which to probe the
residues necessary for the distinction between FosX and FosA activity.  Although
mutations intended to enhance the promiscuous FosA activity of this enzyme (through
creation of a K+ binding loop and enhancement of GSH binding) were not successful,
this enzyme has proven to be an interesting member of the FosX class which may help
illuminate the evolution of the fosfomycin resistance proteins through site-directed
mutagenesis experiments.
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Future work will involve total kinetic characterization of all members of the FosX
class.  In addition, mutagenesis of the M. loti FosX will turn in an alternate direction for
determination of residues necessary for transforming this enzyme into a better FosX
rather than a better FosA.  As more bacterial genomes become available, even more
pathogens harboring fosfomycin resistance proteins may become available for study,
with the intent of gaining a comprehensive understanding of enzyme-mediated
fosfomycin resistance.  Although it is beyond the capacity of this research project, the
ultimate goal is the design of biologically active inhibitors of fosfomycin resistance
proteins in order to restore the clinical usefulness of fosfomycin.
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APPENDIX
Consensus key (see documentation for details)
* - single, fully conserved residue
: - conservation of strong groups
. - conservation of weak groups
  - no consensus
CLUSTAL W (1.81) multiple sequence alignment
L. monocytogenes EGD         MISGLSHITLIVKDLNKTTTFLREIFNAEEIYSSGDQTFSLSKEKFFLIA
L. monocytogenes ATCC        MISGLSHITLIVKDLNKTTAFLQNIFNAEEIYSSGDKTFSLSKEKFFLIA
C. botulinum                 MIERISHITFVVKNLDKTTQLFKELFNAKZVYYSGEKKHFLFKERFFIVG
M. loti                      MIEGLSHMTFIVRDLERMTRILEGVFDAREVYASDTEQFSLSREKFFLIG
B. melitensis                MVQGLSHMTFIVRDLDRMEEILTTVFDARRVYDSGAETFSLSKERFFLIG
PA1129                       MLTGLNHLTLAVADLPASIAFYRDLLGFRLEARWDQG-------AYLELG
                             *:  :.*:*: * :*     :   ::. .     .          :: :.
L. monocytogenes EGD         G----LWICIMEGDSL--QEQTYNHIAFRIQSEEVDEYIERIKSLGVEIK
L. monocytogenes ATCC        G----LWICIMEGDSL--QERTYNHIAFQIQSEEVDEYTERIKALGVEMK
C. botulinum                 S----QWIAVMEDANI--LNRTYHHIAFKISNSDVDNYLDKIKTLNLELK
M. loti                      D----IWVAIMQGEKL--AERSYNHIAFKIDDADFDRYAERVGKLGLDMR
B. melitensis                NGKEPIWIATMEGEPL--PTRTNNHVAFKIANNEYEAYLKRIRALGLEVR
PA1129                       S----LWLCLSREPQYGGPAADYTHYAFGIAAADFARFAAQLRAHGVREW
                             .     *:.  .            * ** *   :   :  ::   .:
L. monocytogenes EGD         PERPRVEGEGRSIYFYDFDNHLFELHAGTLEERLKRYHE----------
L. monocytogenes ATCC        PERPRVQGEGRSIYFYDFDNHLFELHAGTLEERLKRYHE----------
C. botulinum                 PPRRRVSGEGYSIYFYDYDNNLFELHTETLEKRLASYTKIDNI------
M. loti                      PPRPRVEGEGRSIYFYDDDNHMFELHTGTLTERLARKAKGLEAAQ----
B. melitensis                EGRSRVPGEGQSIYFYDDDNHMFELHTGTLDERLKRYGQGR--------
PA1129                       KQNR---SEGDSFYFLDPDGHRLEAHVGDLRSRLAACRQAPYAGMRFAD
                               .    .** *:** * *.: :* *.  * .**    :
FosX Protein MW ε No. aa pki
B. melitensis 16149 13370 140 5.92
L. monocytogenes (ATCC) 15570 13370 134 5.20
L. monocytogenes (EGD) 15654 13370 134 4.90
M. loti 16180 12090 140 5.29
M. loti (K+ loop) 15874 12090 137 5.27
M. loti (E44G/M57S/F34Y, K+ loop) 14022 13370 137
C. botulinum 16396 17210 138 8.59
B. suis 16198 14650 140 5.92
PA1129 (FosA) 15122 26030 136 6.57
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